Search Results - "SUKRI, Norita"

Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies by WONG, Chiung-Ing, KOH, Tong-San, LIM, Robert, SUKRI, Norita, LIM, Siew-Eng, ONG, Ai-Bee, STEINBERG, Joyce, GUPTA, Neeraj, PRADHAN, Rajendra, HUMERICKHOUSE, Rod, GOH, Boon-Cher, SOO, Ross, HARTONO, Septian, THNG, Choon-Hua, MCKEEGAN, Evelyn, YONG, Wei-Peng, CHEN, Chien-Shing, LEE, Soo-Chin, WONG, John

“…To determine the safety and tolerability of ABT-869 at escalating doses and its effects on biomarkers relevant for antiangiogenic activity in patients with…”
Get full text

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity by Fan, Lu, Goh, Boon-Cher, Wong, Chiung-Ing, Sukri, Norita, Lim, Siew-Eng, Tan, Sing-Huang, Guo, Jia-Yi, Lim, Robert, Yap, Hui-Ling, Khoo, Yok-Moi, Iau, Philip, Lee, How-Sung, Lee, Soo-Chin

“…OBJECTIVESDoxorubicin is a cytotoxic drug with potential for severe myelosuppression that is highly variable and poorly predictable. METHODSWe correlated CBR1…”
Get full text

Chemotherapy-induced tumor gene expression changes in human breast cancers by Lee, Soo-Chin, Xu, Xin, Lim, Yi-Wan, Iau, Philip, Sukri, Norita, Lim, Siew-Eng, Yap, Hui Ling, Yeo, Wee-Lee, Tan, Patrick, Tan, Sing-Huang, McLeod, Howard, Goh, Boon-Cher

“…OBJECTIVEStudying chemotherapy-induced gene expression changes in vivo, which could provide insights into mechanisms of chemotherapy resistance. METHODSWe…”
Get full text

A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapy by Koh, Tong San, Thng, Choon Hua, Hartono, Septian, Tai, Bee Choo, Rumpel, Helmut, Ong, Ai Bee, Sukri, Norita, Soo, Ross A., Wong, Chuing Ing, Low, Albert S. C., Humerickhouse, Rod A., Goh, Boon Cher

“…The aim of the present study was to compare three tracer kinetics methods for the analysis of dynamic contrast‐enhanced (DCE) MRI data, namely the generalized…”
Get full text

Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer by Lee, Soo-Chin, Xu, Xin, Chng, Wee-Joo, Watson, Mark, Lim, Yi-Wan, Wong, Chiung-Ing, Iau, Philip, Sukri, Norita, Lim, Siew-Eng, Yap, Hui-Ling, Buhari, Shaik Ahmad, Tan, Patrick, Guo, Jiayi, Chuah, Benjamin, McLeod, Howard L, Goh, Boon-Cher

“…OBJECTIVETumor gene expression signatures have been used to classify, prognosticate, and predict chemotherapy sensitivity in breast cancer, although almost all…”
Get full text

A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers by Yong, Wei-Peng, Wang, Ling-Zhi, Tham, Lai-San, Wong, Chiung-Ing, Lee, Soo-Chin, Soo, Ross, Sukri, Norita, Lee, How-Sung, Goh, Boon-Cher

“…Purpose The aims were to determine the maximum tolerable dose (MTD) of docetaxel with CYP3A inhibition by ketoconazole, and to correlate the pharmacokinetics…”
Get full text

Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug by THAM, Lai-San, LEE, How-Sung, LINGZHI WANG, YONG, Wei-Peng, LU FAN, ONG, Ai-Bee, SUKRI, Norita, SOO, Ross, LEE, Soo-Chin, GOH, Boon-Cher

“…Drugs metabolized by cytochrome CYP3A isoenzymes have wide interindividual variability and normally distributed plasma clearance distributions. This makes…”
Get full text